Scientists at Columbia University College of Dental Medicine have introduced an advanced exosome-based system, "safeEXO-Cas," ...

Antibiotic resistance is a global concern that threatens our ability to prevent and treat bacterial infections in humans and ...

On Tuesday, the team behind the plan to bring mammoth-like animals back to the tundra announced the creation of what it is ...

Scientists are exploring gene editing as a way to correct trisomy at the cellular level. Using CRISPR-Cas9, researchers ...

Fintel reports that on March 5, 2025, HC Wainwright & Co. initiated coverage of Intellia Therapeutics (NasdaqGM:NTLA) with a ...

Gene editing techniques may eventually allow trisomy to be treated at the cellular level, according to an in vitro proof-of-concept study.

CRISPR-Cas9 genome editing exploits the CRISPR-Cas system to modify a genome in a targeted manner. Guided by RNA, the Cas9 endonuclease breaks DNA at a target sequence. Imprecise repair of the ...

When the CRISPR Cas9 protein is added to a cell along with a piece of guide RNA, the Cas9 protein hooks up with the guide RNA and then moves along the strands of DNA until it finds and binds to a ...

The system has also been designed to satisfy ... Cyto-Mine for precision genome editing with technologies such as CRISPR–Cas9. Genome editing offers the potential to create new therapies and ...

The CRISPR/Cas9 gene-editing system, based on a bacterial immune response against viruses, has been applied to human genome editing and was recently implemented in the first Food and Drug ...

Among his recent work at Drexel is the development of technologies based on the CRISPR-Cas9 system for genome mapping and sequencing, which have broad applications in molecular diagnostics, cell/gene ...

Intellia Therapeutics, Inc. is a clinical stage genome editing company, which engages in the development of curative therapeutics using the CRISPR/Cas9 system. Its CRISPR/Cas9 system transforms ...